MedTrace Logo

Clinical Impact and Utility of Digital Health Solutions in Participants Receiving Systemic Treatment in Clinical Practice

NCT05694013 · Status: TERMINATED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2025-10-22

Study results available
· View outcomes & findings →

Summary

This study will evaluate the clinical impact and utility of digital health solutions (DHS) on health outcomes and health-care resource utilization in people receiving systemic anti-cancer treatment (approved or non-approved) in clinical practice.

Conditions

Interventions

DEVICE

Roche DPM Module

Participants will be trained in the use of the Roche DPM Module, which they will use alongside local SOC support

DRUG

Atezolizumab SC

Participants will receive atezolizumab SC for 16 cycles (cycle length = 21 days)

OTHER

Local SOC support

Participants will receive local SOC support

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-LaRoche

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-27
Primary Completion
2024-06-30
Completion
2024-06-30

Countries

  • Australia
  • Austria
  • Germany
  • Spain
  • Switzerland

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05694013 on ClinicalTrials.gov